Meanwhile, the landscape-changing “Magacurve” for advanced NSCLC showed the therapeutic successes of PD1/PD-L1 blockade (23), even though the monotherapy of anti-PD1/PD-L1 mAb resulted in positive response of only ~ 15-30% of NSCLC patients (24). Here, PDCD1 is linked to non-small cell lung carcinoma.